"Sodium" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A member of the alkali group of metals. It has the atomic symbol Na, atomic number 11, and atomic weight 23.
| Descriptor ID |
D012964
|
| MeSH Number(s) |
D01.268.549.750 D01.268.557.650 D01.552.528.850 D01.552.547.725
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sodium".
Below are MeSH descriptors whose meaning is more specific than "Sodium".
This graph shows the total number of publications written about "Sodium" by people in this website by year, and whether "Sodium" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 6 | 6 |
| 1996 | 0 | 6 | 6 |
| 1997 | 1 | 4 | 5 |
| 1998 | 3 | 3 | 6 |
| 1999 | 3 | 1 | 4 |
| 2000 | 1 | 2 | 3 |
| 2001 | 3 | 6 | 9 |
| 2002 | 3 | 9 | 12 |
| 2003 | 3 | 0 | 3 |
| 2004 | 4 | 4 | 8 |
| 2005 | 1 | 2 | 3 |
| 2006 | 0 | 4 | 4 |
| 2007 | 1 | 3 | 4 |
| 2008 | 5 | 3 | 8 |
| 2009 | 2 | 2 | 4 |
| 2010 | 4 | 0 | 4 |
| 2011 | 4 | 1 | 5 |
| 2012 | 2 | 3 | 5 |
| 2013 | 1 | 2 | 3 |
| 2015 | 1 | 5 | 6 |
| 2016 | 0 | 5 | 5 |
| 2017 | 2 | 5 | 7 |
| 2018 | 2 | 4 | 6 |
| 2019 | 1 | 2 | 3 |
| 2020 | 1 | 3 | 4 |
| 2021 | 1 | 2 | 3 |
| 2022 | 0 | 11 | 11 |
| 2023 | 1 | 2 | 3 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sodium" by people in Profiles.
-
Differentiating the contributions of Na+/K+ pump current and persistent Na+ current in simulated voltage-clamp experiments. J Neurophysiol. 2025 Mar 01; 133(3):904-923.
-
A DNA nanodevice for mapping sodium at single-organelle resolution. Nat Biotechnol. 2024 Jul; 42(7):1075-1083.
-
Association of Prescription Co-payment With Adherence to Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Therapies in Patients With Heart Failure and Diabetes. JAMA Netw Open. 2023 06 01; 6(6):e2316290.
-
The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials. Diabetes Obes Metab. 2023 08; 25(8):2151-2162.
-
The ion transporter Na+-K+-ATPase enables pathological B cell survival in the kidney microenvironment of lupus nephritis. Sci Adv. 2023 02 03; 9(5):eadf8156.
-
Transcriptional Dysregulation Underlies Both Monogenic Arrhythmia Syndrome and Common Modifiers of Cardiac Repolarization. Circulation. 2023 03 07; 147(10):824-840.
-
Measuring copeptin, a surrogate for vasopressin in patients with hypertension - Can it identify those who are volume Responsive? Clin Biochem. 2023 Feb; 112:48-52.
-
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis. Diabetes Care. 2022 12 01; 45(12):2991-2998.
-
Hyponatremia Is a Powerful Predictor of Poor Prognosis in Left Ventricular Assist Device Patients. ASAIO J. 2022 12 01; 68(12):1475-1482.
-
Clinical Effectiveness of Calcium Oxalate Stone Treatments. Am J Nephrol. 2022; 53(10):761-766.